Proteasome inhibitor and IMiDs before and after autologous stem cell transplantation for untreated multiple myeloma aiming normalization of para-protei
- Conditions
- multiple myeloma
- Registration Number
- JPRN-UMIN000012465
- Lead Sponsor
- Division of Hematology, Saitama Medical Center, Jichi Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 64
Not provided
1) Patients with a history of allergy to the drugs used in the protocol therapy 2) Patients who can not be expected to survive more than 3 months 3) Patients who suffered another carcinoma within 5 years 4) Patients with HBs antigen-positive, or HCV antibody-positive, or HIV antibody-positive 5) Patients who have peripheral neuropathy or peripheral neuropathic pain of grade 2 or more. 6) Patients with serious active infection or patients who are suspected to have serious active infection infections 7) Patients with serious mental disorders 8) Patients with serious pulmonary dysfunction 9) Patients with interstitial pneumonia or pulmonary fibrosis 10) Patients with serious heart dysfunction 11) Patients with poorly controlled diabetes 12) Patients receiving hemodialysis 13) Patient who are or may be pregnant or are nursing 14) Patients who are determined to be inappropriate for study by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method